The company is yet to begin negotiations in other countries, including France, Italy and Spain.īeyond 2020 The company expects its cystic fibrosis business to continue growing beyond 2020, despite Kaftrio now entering the "flat part" of the launch curve. "There are a number of things which are going to be different, which leads us to believe that the exact trajectory of the launch is difficult to call."Įarlier in June, Vertex expanded its 2019 access agreement with the National Health Service in England to include Kaftrio ahead of the European approval. " process is likely to take a bit longer in Europe than it did here in the U.S.," Arbuckle noted. "The actual rate and level of uptake that we will see in 2020 in Europe is unpredictable, given the ongoing pandemic and the fact that we are conducting a virtual launch."Īdditionally, the company does not have many reimbursement agreements in place in Europe yet, whereas in the U.S., Vertex was able to secure rapid public and private reimbursement.
"We have incorporated some incremental European revenues for Kaftrio into our revised 2020 revenue guidance," CFO Charles Wagner said on the call. The company raised its revenue outlook for 2020.
Nevertheless, Vertex expects the high compliance and persistence rates as well as high patient inventory levels seen since the launch of the drug to normalize in the second half of the year. The Boston-based biotechnology company's profits soared in the second quarter largely because of high uptake of the drug in the U.S, where it is known as Trikafta. expects to gain approval from the European Commission for its triple combination cystic fibrosis drug, branded Kaftrio in Europe, in the next few months, which could enable the treatment of up to 10,000 new patients, Chief Commercial Officer Stuart Arbuckle said on a July 30 earnings call.
0 kommentar(er)
